**Adjuvant Therapeutic Strategies for Squamous Cell Carcinoma**

76 Squamous Cell Carcinoma

[11] Wain, S. L., R. Kier, R. T. Vollmer, and E. H. Bossen. 1986. Basaloid-squamous

[12] Choussy, O., M. Bertrand, A. Francois, E. Blot, H. Hamidou, and D. Dehesdin. Basaloid

[13] Kwon, Y. S., Y. M. Kim, G. W. Choi, Y. T. Kim, and J. H. Nam. 2009. Pure basaloid

[14] Nagakawa, H., K. Hiroshima, Y. Takiguchi, M. Yatomi, Y. Takahashi, M. Mikami, Y.

[15] Neves, T. R., M. J. Soares, P. G. Monteiro, M. S. Lima, and H. G. Monteiro. Basaloid

[16] Vasudev, P., O. Boutross-Tadross, and J. Radhi. 2009. Basaloid squamous cell

[17] Wieneke JA, Thompson L, Weng BM Basaloid squamous cell carcinoma of sinonasal

[18] Kleist B, Bankau A, Lorenz G, Jäger B, Poetsch M. Laryngoscope 2004 Different risk factors in basaloid and common squamous head and neck cancer.114(6):1063-8. [19] Thariat, J., C. Badoual, C. Faure, C. Butori, P. Y. Marcy, and C. A. Righini. Basaloid

[20] Friedrich RE, Sperber C, Jäkel T, Röser K, Löning T Basaloid lesions of oral squamous

[21] Thariat J, Ahamad A, El-Naggar AK, Williams MD, Holsinger FC, Glisson BS, Allen PK,

[22] Hewan-Lowe, K., and I. Dardick.. Ultrastructural distinction of basaloid-squamous carcinoma and adenoid cystic carcinoma. Ultrastruct Pathol 1995; 19:371-81. [23] Kim K H, Sung M W et al Adeniod cystic carcinoma of the head and neck.Arch

[24] Azorín D, López-Ríos F, Ballestín C, Barrientos N, Rodríguez-Peralto JL. Primary

[25] Paulino A, Singh M, Shah A, Huvos A. Basaloid Squamous Cell Carcinoma of the Head

Surg Pathol. 2010 Feb;34(2):223-30.

a young woman. Int J Clin Oncol 11:66-8.

carcinoma: two case reports. Cases J 2:9351.

treatment and prognosis. J Clin Pathol 63:857-66.

Otolaryngol,Head Neck Surg 1994,120;721-726.

17:1158-66.

Otol:1-6.

24:542-5.

Oncol 29:e440-2.

tract, cancer 1999;85.841-854

Anticancer Res ;30(5):1605-12.

Cancer 2008 Jun 15;112(12):2698-709.

Cutan Pathol. 2001 Nov; 28(10):542-5.

2000.

clinicopathologic features, differential diagnosis, and outcome of 35 cases Am J

carcinoma of the tongue, hypopharynx, and larynx: report of 10 cases. Hum Pathol

squamous cell carcinoma of the head and neck: report of 18 cases. J Laryngol

squamous cell carcinoma of the uterine cervix: a case report. J Korean Med Sci

Nakatani, and T. Kuriyama. 2006. Basaloid squamous-cell carcinoma of the lung in

squamous cell carcinoma in the urinary bladder with small-cell carcinoma. J Clin

squamous cell carcinoma of the head and neck: role of HPV and implication in

epithelial cells and their association with HPV infection and P16 expression.

Morrison WH, Weber RS, Ang KK, Garden AS. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study.

cutanous, adenosquamous carcinoma case report and review of the litreture .J

and Neck. The Laryngoscope Volume 110, Issue 9, pages 1479–1482, September

**5** 

*Japan* 

Tadahiro Shoji et al.\*

**Neoadjuvant Chemotherapy** 

*Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine* 

**Using Platinum-Based Regimens for Stage** 

**Non-Squamous Cell Carcinoma of the Cervix** 

The methods used for treating stage Ib2-IIb cervical cancers, with a bulky mass, differ between Japan and Western countries. In Western countries, concurrent chemoradiation (CCRT) has been recommended as a standard therapy for such tumors based on the results of multiple large-scale randomized trials and meta-analyses (Morris et al., 1999; Rose et al., 1999; Whitney et al., 1999; Pearcey et al., 2002; Eifel et al. 2004; Green et al. 2001; Lukka et al., 2002). In Japan, Korea, Italy and some other countries, the neoadjuvant chemotherapy (NAC) approach has been extensively introduced to clinical practice (Sugiyama et al., 1999). NAC is considered to be clinically significant in 2 respects: it is expected to improve the radicality and safety of surgery by reducing tumor size; and it is expected to exert systemic effects, i.e., effects on lymph node occult micrometastases, etc. A disadvantage of NAC is delayed initiation of the primary treatment, suggesting the necessity of completing NAC as an auxiliary therapy within a short period of time. Therefore, we may find that NAC is valuable if it can exert efficacy rapidly with high platinum dose intensity (DI), assuring that subsequent primary surgical therapy can be performed as soon as possible. At our facility, a platinum-based regimen has been used for NAC in patients with cervical cancer. Herein, we review the efficacy and safety data on NAC for squamous cell carcinoma of the uterine cervix. We previously reported our interim data and now present the results of an ongoing pilot study on the efficacy and safety of

We studied 43 patients with locally advanced cancer of the uterine cervix (clinical stage Ib2 to IIb) who gave informed consent to participate in this study between January 2002 and

\*Eriko Takatori, Hideo Omi, Masahiro Kagabu, Tastuya Honda, Yuichi Morohara, Seisuke Kumagai,

*Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Japan* 

NAC for non-squamous cell carcinoma of the uterine cervix.

Fumiharu Miura, Satoshi Takeuchi, Akira Yoshizaki and Toru Sugiyama

**2. Subjects and methods** 

**2.1 Subjects** 

**1. Introduction** 

**Ib2-II Squamous Cell Carcinoma and** 
